The purpose of this manuscript is to review the design, development and clinical results of the light adjustable lens (LAL). Evolution in techniques, biometry and intraocular lens (IOL) calculation have improved outcomes and increased expectations after cataract surgery. Nevertheless, Imprecise IOL power determinations, pre-existing and surgical-induced astigmatism, and previous corneal refractive surgery continue to limit post-operative uncorrected vision. The LAL was designed to provide a stable, precise correction of refractive errors with a safe, non-invasive post-operative procedure. The concept behind the LAL is based on photochemistry and 
The concept of an intraocular lens (IOL) that can be adjusted in vivo has been hypothesised and studied since phacoemulsification became the standard of care in cataract surgery 1 and its potential benefits have been recognised by previous investigators. [2] [3] [4] The first published report of a multicomponent IOL that could be adjusted after implantation came in 1996. 5 Kraser 2 patented a three-piece IOL with an inflatable diaphragm in which injection or removal of fluid from the flexible optic is used to post-operatively adjust the IOL power.
Eggleston 3 patented a mechanically adjustable IOL whose power is adjusted by rotation of the optic in a screw guide 6 and later reported on the possibility of performing the adjustment non-invasively with the use of samarium and cobalt magnets. 
Design and Development
Silicone was selected for the LAL technology because of its optical clarity, ability to be folded during insertion and history of safe use in IOLs. The silicone formulation used in the LAL is based upon a silicone matrix system comprised of polymer, resin, crosslinker and platinum catalyst. Formulated into the silicone matrix are a photoreactive macromer, photoinitiator and ultraviolet (UV) absorbers.
The photosensitive macromer system was designed to be compatible with the silicone matrix and insoluble in water to prevent leaching into the eye. It also was formulated to remain optically clear upon forming an interpenetrating network within the matrix upon irradiation with UV light. 4 The LAL is a three-piece silicone lens with blue poly(methyl methacrylate) (PMMA) modified-C haptics. The optic has a diameter of 6 mm, 8 a 360-degree square edge on the posterior surface to minimise posterior capsular opacification (PCO) 9 and an enhanced UV protection layer in the posterior aspect to minimise erythropsia from retinal UV exposure. 10 The basic concept behind the LAL is based on the principles of photochemistry and diffusion. 11 The optic consists of partially polymerised macromers with an appropriately bonded photo-sensitiser.
The adjustment is based upon the principle that all non-attached solutes will equally distribute themselves throughout the lens optic. diffuse toward the irradiated region to once again establish uniform concentration throughout the matrix. As the macromers migrate centrally, this portion of the lens swells and refractive power increases to correct hyperopia. 4 Refractive adjustments are made with the light delivery device (LDD)
by delivering light of the selected wavelength, spatial intensity profile, and diameter to produce a predictable change in the power of the LAL.
The LDD consists of a UV light source, projection optics, and control
interface. An apodised filter is included in the optical assembly to create a specific beam-intensity profile projected onto the implanted lens. 4 The LDD generates and projects a spatial irradiance pattern onto the LAL using a digital mirror device. The surgeon centres and focuses the treatment beam on the LAL using an alignment reticule while patient alignment is achieved using a fixation target, paracentral to the delivery beam. The LDD is capable of correcting myopia, hyperopia and astigmatism. 13 Customised multifocal profiles, as well as spherical aberration and other higher-order aberrations treatments can be designed with the LDD. The same group at the University of Utah performed a retina safety study 16 Before any human trials, extensive in vitro and in vivo studies where performed in regards to cytotoxicity, hydrolytic stability, photostability, optical performance and biocompatibility to ensure the safety and quality of the LAL and the irradiation procedure. 4 Discussion of the results of these studies is beyond the scope of this review.
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of increased intraocular pressure which normalised without the need for topical therapy and two patients that suffered from dry eye syndrome. None of these adverse events were attributed to the LAL or the irradiation protocol.
Only one case of a complication inherent to the LAL has been reported in the literature. 25 A 57-year-old female that, after uneventful phacoemulsification with implantation of a LAL and the first adjustment procedure, returned with a decrease in BCVA to 20/125
and a refraction of -3.25 D. A distinct paracentral elevation in the lens was noted on slit lamp examination. Upon questioning, the patient admitted she had not used the UV protecting glasses at several occasions during the post-operative period and had exposed herself to sunlight for several hours. This case underscores the importance of compliance with post-operative UV protection glasses, something that must be stressed by the surgeon and staff in order to ensure the desired outcome.
An important caveat in patient selection is that a pre-operative dilated pupil size larger than 7.0 mm must be confirmed before implantation off the LAL, since this is the pupil size needed postoperatively for the adjustments and specially the lock-in procedure.
It is clear from the previous studies that the LAL can be adjusted postoperatively to correct myopia, 11, 19 hypermetropia 17, 18 and astigmatism 20, 21 with great precision. The next challenge for this technology is to address presbyopia. 14, 21 For this purpose, the easiest, already available option is monovision. Monovision can be created by adjusting the LAL to the desired amount of myopia, then the patient is given time to adjust to his monovision, which, in case the patient cannot adapt or is not happy, can be further modified or completely reversed with a second adjustment before the lock-in of the lens, something that can only be done with this technology. Another area that is currently under development is a multifocal profile in which a small near zone can be added during a subsequent adjustment, after all sphero-cylindrical error has been corrected, allowing the size, power and location of the add zone to be customised to the patient. Results from a pilot study with this approach, reached uncorrected distance visual acuity of 20/25 in 83.3 % of the eyes and uncorrected near visual acuity of J2 in 87.5 % of the eyes. 26 Another approach to presbyopia with the LAL that is being pursued, consists of increasing the asphericity of the lens with the LDD to increasing depth of focus. 
Discussion
As cataract surgery has evolved and small incision phacoemulsification has become the dominant procedure, surgeons have been on a continual quest to provide patients with an emmetropic visual outcome. 1 As visual outcomes have improved over the years with developments in biometry and IOL calculation formulas, [29] [30] [31] patients have become more demanding, expecting at least emmetropia if not presbyopic correction.
With current methods of IOL power determination, the vast majority of patients achieve a UCVA of 20/40 or better. A much smaller percentage achieves optimal vision without spectacles. 1 The variables that affect post-operative UCVA include imprecise IOL power determinations, pre-existing corneal astigmatism, surgical induced astigmatism and previous corneal refractive surgery. [32] [33] [34] [35] [36] With The Light Adjustable Lens -A Review
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